Bristol Myers Squibb has opened its radiopharmaceutical manufacturing facility in Indianapolis, which played a major role in ...

The Bristol Myers Squibb subsidiary RayzeBio has opened a new 77,000-square-foot facility in Indianapolis, Indiana.

RayzeBio has additional programs for hepatocellular carcinoma. Between $20 million and $25 million is set aside for RYZ801 and RYZ811, advancing both programs in this type of liver cancer through ...

RayzeBio thinks its Ac225 RPT is the next generation in RPT development. The company thinks there are 7000 target patients per year. Rival drug price median is a quarter million dollars.

RayzeBio's $4.1 billion deal to be acquired by Bristol Myers caps a brief but lucrative run as a public company for the radiopharmaceutical firm. RayzeBio went public in September at $18 a share ...

SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (Nasdaq: RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today ...

Initiating RayzeBio, Inc. coverage with a Buy rating and common stock price target of $43 based on my risk-adjusted NPV discounted cash flow model, representing a 110% upside.

Neumora and RayzeBio are both casting a line into the market, with each seeking to raise more than $200 million in initial public offerings this fall. Neumora is offering 14,710,000 shares at a ...

Rayzebio, Inc. SAN DIEGO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (Nasdaq: RYZB), a biopharmaceutical company developing an innovative radiopharmaceutical pipeline to treat different ...

RayzeBio, started four years earlier, had gone public only a few months before the pharma giant swept in and acquired its pipeline of radiopharmaceutical candidates. It was the third company Song ...

RayzeBio co-founder, industry veterans launch new biotech VC with $310 million. By Allison DeAngelis Feb. 7, 2024. Reprints. Adobe. T hree biotech VC veterans, including one of the co-founders of ...